Last edition
News about "EU orphan drug designation"
Vanda Pharma's Imsidolimab Gets EU Orphan Designation for Psoriasis
Vanda Pharmaceuticals’ imsidolimab receives European Union (EU) orphan designation for Generalised Pustular Psoriasis (GPP), marking the first such designation for a GPP treatment in the EU.
EU Orphan Drug Designation | 26/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members